Subtype
Liver Neoplasm
CI-CAN-00001077Explore in graph →
Non-malignant930 active trials14 approved drugs17 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001077Explore in graph →
Clinical trials
4,334 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03766555 | Microwave Ablation Versus Liver Resection For Early Hepatocellular Carcinoma in Patients With Borderline Liver Function | unknown | N/A | 76 | Chinese University of Hong KongOTHER | 1 | Feb 13, 2023 | clinicaltrials |
| NCT05543304 | Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC) | unknown | — | 200 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Feb 13, 2023 |
| clinicaltrials |
| NCT05721300 | Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer | unknown | N/A | 2,215 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT04417764 | TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma. | unknown | Phase 1 | 10 | Central South UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05719480 | A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Liver Cancer | unknown | — | 2,000 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05029973 | HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05225116 | Safety and Efficacy of Lenvatinib and Anti-PD1 Antibody Combined With Radiotherapy Neoadjuvant Treatment for Resectable Hepatocellular Carcinoma With PVTT | unknown | Phase 1 | 20 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05716620 | Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 380 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT03099564 | Pembrolizumab Plus Y90 Radioembolization in HCC Subjects | unknown | Early Phase 1 | 30 | Ashwin SomasundaramOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04911959 | Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC | unknown | Phase 1 / Phase 2 | 50 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT04612504 | SynOV1.1 Intratumoral Injection Study | unknown | Phase 1 | 15 | Beijing Syngentech Co., Ltd.INDUSTRY | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05701553 | Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage Hepatocellular Carcinoma | unknown | — | 20 | Shanghai Zhongshan HospitalOTHER | 1 | Feb 2, 2023 | clinicaltrials |
| NCT05609695 | Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeted Drugs / Locoregional Therapy in the Treatment of Hepatocellular Carcinoma | unknown | — | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 31, 2023 | clinicaltrials |
| NCT02125396 | Adjuvant Radiotherapy Comparing TACE for Curative HCC(ARTC-HCC) | unknown | Phase 3 | 150 | Guangxi Medical UniversityOTHER | 1 | Jan 27, 2023 | clinicaltrials |
| NCT05131698 | Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular Carcinoma | unknown | Early Phase 1 | 31 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05312216 | Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 25 | Zhejiang UniversityOTHER | 1 | Jan 26, 2023 | clinicaltrials |
| NCT05694949 | Main Postoperative Complications After COVID-19 | unknown | — | 100,000 | RenJi HospitalOTHER | 0 | Jan 25, 2023 | clinicaltrials |
| NCT05693519 | GastroIntestinal Cancer in Children and Adolescents(GICCA) | unknown | — | 2,500 | Paul G. Kemps, MDOTHER | 1 | Jan 23, 2023 | clinicaltrials |
| NCT04213118 | Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery Recurrence(ALTER-H-004) | unknown | Phase 2 | 30 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jan 17, 2023 | clinicaltrials |
| NCT05677724 | Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment | unknown | — | 20 | Fubing WangOTHER | 1 | Jan 10, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05668793 | GNB4 and Riplet Gene Methylation Combined Detection Kit (Fluorescence PCR Method) | unknown | — | 1,000 | Wuhan Ammunition Life-tech Co., LtdINDUSTRY | 0 | Dec 30, 2022 | clinicaltrials |
| NCT05280444 | Lipiodol-TACE With Idarubicin for Hepatocellular Carcinoma | unknown | Phase 2 / Phase 3 | 216 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05344924 | TACE Combined With Penpulimab and Anlotinib for Advanced HCC | unknown | Phase 2 / Phase 3 | 109 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05557656 | A Real World Study of Regogfinib in HCC | unknown | — | 800 | Zhongda HospitalOTHER | 0 | Dec 29, 2022 | clinicaltrials |
| NCT05631613 | Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma | unknown | — | 40 | Zhongda HospitalOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05662488 | FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy | unknown | — | 25 | Peking Union Medical College HospitalOTHER | 1 | Dec 22, 2022 | clinicaltrials |
| NCT05578430 | AK104 Combining With TACE for Resectable Hepatocellular Carcinoma (MORNING) | unknown | Phase 2 | 54 | Sun Yat-sen UniversityOTHER | 0 | Dec 15, 2022 | clinicaltrials |
| NCT05361538 | Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm | unknown | N/A | 60 | Tianjin Third Central HospitalOTHER | 1 | Dec 14, 2022 | clinicaltrials |
| NCT05650151 | Peri-operative Vitamin D Therapy for Hepatectomy | unknown | N/A | 200 | National Taiwan University HospitalOTHER | 0 | Dec 14, 2022 | clinicaltrials |
| NCT04212273 | Diagnostic Efficacies of Sonazoid-CEUS and EOB-MRI in Patients With High Risk of HCC | unknown | N/A | 200 | Tianjin Third Central HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05360420 | Diagnosis of Nodules ≤2 cm Based on US and CEUS Compared With Current Clinical Procedure | unknown | N/A | 6,730 | Tianjin Third Central HospitalOTHER | 1 | Dec 13, 2022 | clinicaltrials |
| NCT05643417 | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy | unknown | Phase 1 | 80 | Fudan UniversityOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT04503902 | Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 1 / Phase 2 | 46 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 29, 2022 | clinicaltrials |
| NCT05627297 | Applying Artificial Intelligence to Optimize Early-stage Hepatocellular Carcinoma Treatment Based on Multi-modal Image(AI-HCC) | unknown | — | 200 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Nov 25, 2022 | clinicaltrials |
| NCT05622825 | Valuation of the Safety and Efficacy of Combination of Cryoablation and Dendric Cell/Cytokine-induced Killers Cells Treatment for Advanced Liver Cancers | unknown | Phase 1 / Phase 2 | 15 | National Taiwan University HospitalOTHER | 0 | Nov 21, 2022 | clinicaltrials |
| NCT05620004 | Safety and Efficacy of Bifidobacterium Therapy in Patients With Advanced Liver Cancer Receiving Immunotherapy | unknown | Phase 1 / Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05617430 | Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 43 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Nov 15, 2022 | clinicaltrials |
| NCT05614466 | The SIMPLY-B Study | unknown | N/A | 100 | Nadine BarnesOTHER | 0 | Nov 14, 2022 | clinicaltrials |
| NCT04718909 | Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCC(REGSIN) | unknown | Phase 2 | 166 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00986661 | A Study to Assess PV-10 Chemoablation of Cancer of the Liver | unknown | Phase 1 | 78 | Provectus Biopharmaceuticals, Inc.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05603039 | A Phase Ib/II Trial to Evaluate the Safety and Efficacy of QL1706 in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 80 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05598268 | A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors. | unknown | Phase 1 / Phase 2 | 74 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Oct 28, 2022 | clinicaltrials |
| NCT05575622 | Clinical Study for Combined Analysis of CTC and Exosomes on Predicting the Efficacy of Immunotherapy in Patients With Hepatocellular Carcinoma | unknown | — | 200 | Zhongnan HospitalOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT05257694 | Clinical Decision Biological Biomarker and Prognosis Prediction of Hepatocellular Carcinoma by Deep Learning | unknown | — | 1 | Ping LiangOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT05587556 | Analysis of Clinical Outcomes and Complications in Patients Received Liver Transplantation: A Retrospective Study | unknown | — | 1,400 | China Medical University HospitalOTHER | 1 | Oct 20, 2022 | clinicaltrials |
| NCT05573282 | Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma | unknown | — | 50 | Sun Yat-sen UniversityOTHER | 1 | Oct 18, 2022 | clinicaltrials |
| NCT05582278 | HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC | unknown | Phase 2 | 60 | Wen LiOTHER | 1 | Oct 17, 2022 | clinicaltrials |
| NCT05580224 | Anatomical Radiofrequency Ablation for Small Hepatocellular Carcinoma | unknown | N/A | 87 | Seoul National University HospitalOTHER | 1 | Oct 14, 2022 | clinicaltrials |
| NCT05580835 | PET / MR With PSMA for Diagnosis and Staging of Hepatocellular Carcinoma | unknown | N/A | 100 | University of Sao PauloOTHER | 1 | Oct 14, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Feb 13, 2023source: clinicaltrials